

Supplementary Documents [IFRS]

Financial results for the first three months of the fiscal year 2022 (FY2022)

Astellas Pharma Inc.

- Q1/FY2022 Financial Results
- Pipeline list

Cautionary Notes

In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice.

1. Consolidated Results (Full Basis)

Unit: B¥

	Unit: B¥				FY21 Full Year	Change from FY21	
	FY21 APR. - JUN.	FY22 APR. - JUN.	Change	Change (%)		FY22 Full Year	Change (%)
Revenue	326.1	381.8	55.6	17.1%	1,296.2	1,443.0	11.3%
Cost of sales	62.2	88.9	26.6	42.8%	253.0		
Ratio to Revenue	19.1%	23.3%			19.5%		
Gross profit	263.9	292.9	29.0	11.0%	1,043.2		
SG&A expenses	137.1	153.4	16.3	11.9%	548.8	598.0	9.0%
Ratio to Revenue	42.0%	40.2%			42.3%	41.4%	
XTANDI co-promotion fee in the United states	34.5	43.1	8.6	25.1%	139.3	182.0	30.6%
Personnel expenses	49.0	51.2	2.2	4.5%	191.4		
Advertising and Sales Promotion and Other	53.6	59.1	5.4	10.1%	218.1		
R&D expenses	58.3	74.0	15.7	26.9%	246.0	254.0	3.2%
Ratio to Revenue	17.9%	19.4%			19.0%	17.6%	
Amortisation of intangible assets	6.0	10.7	4.8	80.2%	28.3		
Gain on divestiture of intangible assets	-	0.2	0.2	-	24.2		
Share of profit (loss) of investments accounted for using equity method	0.3	0.3	0.1	19.8%	0.5		
Other income	0.4	16.3	15.9	-	15.3		
Net foreign exchange gains	0.3	14.1	13.7	-	8.2		
Fair value remeasurements on contingent consideration	-	1.5	1.5	-	5.4		
Other expenses	27.1	38.4	11.3	41.7%	104.3		
Impairment losses	26.1	22.0	-4.0	-15.4%	74.9		
Fair value remeasurements on contingent consideration	0.0	15.8	15.8	-	7.0		
Operating profit	36.1	33.1	-2.9	-8.2%	155.7	269.0	72.8%
Ratio to Revenue	11.1%	8.7%			12.0%	18.6%	
Finance income	1.5	0.9	-0.5	-36.3%	6.1		
Finance expenses	1.7	2.4	0.7	39.6%	4.9		
Profit before tax	35.8	31.7	-4.2	-11.6%	156.9	267.0	70.2%
Ratio to Revenue	11.0%	8.3%			12.1%	18.5%	
Income tax expense	5.1	6.9	1.7	33.5%	32.8		
Profit	30.7	24.8	-5.9	-19.1%	124.1	208.0	67.6%
Ratio to Revenue	9.4%	6.5%			9.6%	14.4%	
Comprehensive income	36.2	134.4	98.2	271.2%	208.1		

2. Consolidated Results (Core Basis)

Unit: B¥

	Unit: B¥				FY21 Full Year	Forecasts	
	FY21 APR. - JUN.	FY22 APR. - JUN.	Change	Change (%)		FY22 Full Year	Change from FY21
Revenue	326.1	381.8	55.6	17.1%	1,296.2	1,443.0	11.3%
Cost of sales	62.2	88.9	26.6	42.8%	253.0		
Ratio to Revenue	19.1%	23.3%			19.5%		
Gross profit	263.9	292.9	29.0	11.0%	1,043.2		
SG&A expenses	137.1	153.4	16.3	11.9%	548.8	598.0	9.0%
Ratio to Revenue	42.0%	40.2%			42.3%	41.4%	
XTANDI co-promotion fee in the United states	34.5	43.1	8.6	25.1%	139.3	182.0	30.6%
Personnel expenses	49.0	51.2	2.2	4.5%	191.4		
Advertising and Sales Promotion and Other	53.6	59.1	5.4	10.1%	218.1		
R&D expenses	58.3	74.0	15.7	26.9%	246.0	254.0	3.2%
Ratio to Revenue	17.9%	19.4%			19.0%	17.6%	
Amortisation of intangible assets	6.0	10.7	4.8	80.2%	28.3		
Gain on divestiture of intangible assets	-	0.2	0.2	-	24.2		
Share of profit (loss) of investments accounted for using equity method	0.3	0.3	0.1	19.8%	0.5		
Operating profit	62.8	55.3	-7.5	-12.0%	244.7	290.0	18.5%
Ratio to Revenue	19.3%	14.5%			18.9%	20.1%	
Finance income	1.5	0.9	-0.5	-36.3%	6.1		
Finance expenses	1.7	2.4	0.7	39.6%	4.9		
Profit before tax	62.6	53.8	-8.7	-14.0%	245.9		
Ratio to Revenue	19.2%	14.1%			19.0%		
Income tax expense	13.3	8.0	-5.3	-40.1%	55.4		
Profit	49.2	45.8	-3.4	-6.9%	190.6	223.0	17.0%
Ratio to Revenue	15.1%	12.0%			14.7%	15.5%	

3. Exchange Rate

Unit: yen

	Unit: yen				FY21 Full Year	Forecasts	
	FY21 APR. - JUN.Ave.	FY22 APR. - JUN.Ave.	FY21 End	FY22 Q1 End		FY21 Full Year	FY22 Full Year
USD/Yen	109	130	122	136	112	120	
EUR/Yen	132	138	135	142	131	135	

* Fx impacts: Revenue +35.5 billion yen and Core operating profit -7.4 billion yen

* Fx impact on elimination of unrealized profit: COGs ratio +3.2ppt

4. Reconciliation of Full Basis to Core Basis

Unit: B¥

	FY21 APR. - JUN.			FY22 APR. - JUN.		
	Full basis	Adjustment	Core basis	Full basis	Adjustment	Core basis
Revenue	326.1	-	326.1	381.8	-	381.8
Cost of sales	62.2	-	62.2	88.9	-	88.9
Gross profit	263.9	-	263.9	292.9	-	292.9
SG&A expenses	137.1	-	137.1	153.4	-	153.4
R&D expenses	58.3	-	58.3	74.0	-	74.0
Amortisation of intangible assets	6.0	-	6.0	10.7	-	10.7
Gain on divestiture of intangible assets	-	-	-	0.2	-	0.2
Share of profit (loss) of investments accounted for using equity method	0.3	-	0.3	0.3	-	0.3
Other income *	0.4	-0.4	-	16.3	-16.3	-
Other expenses *	27.1	-27.1	-	38.4	-38.4	-
Operating profit	36.1	26.7	62.8	33.1	22.1	55.3
Finance income	1.5	-	1.5	0.9	-	0.9
Finance expenses	1.7	-	1.7	2.4	-	2.4
Profit before tax	35.8	26.7	62.6	31.7	22.1	53.8
Income tax expense	5.1	8.2	13.3	6.9	1.1	8.0
Profit	30.7	18.6	49.2	24.8	21.0	45.8

* "Other income" and "Other expenses" are excluded from Core basis results.

"Other income" and "Other expenses" include gain/loss on sale and disposal of property, plant and equipment, impairment losses, restructuring costs, litigation costs and foreign exchange gains/losses, etc.

5. Revenue by Region

Unit: B¥

	FY21 APR. - JUN.	FY22 APR. - JUN.	Change	Change (%)
Revenue	326.1	381.8	55.6	17.1%
Japan	67.5	66.8	-0.7	-1.0%
Ratio to Revenue	20.7%	17.5%		
United States	133.6	160.9	27.2	20.4%
Ratio to Revenue	41.0%	42.1%		
Established Markets	78.0	88.7	10.7	13.7%
Ratio to Revenue	23.9%	23.2%		
Greater China	16.4	23.2	6.7	41.0%
Ratio to Revenue	5.0%	6.1%		
International Markets	27.8	31.8	4.0	14.5%
Ratio to Revenue	8.5%	8.3%		
Others	2.8	10.4	7.6	273.9%
Ratio to Revenue	0.9%	2.7%		

- Established Markets: Europe, Canada, Australia

- Greater China: China, Hong Kong, Taiwan

- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.

	FY21 Full Year	Forecasts FY22 Full Year	Change from FY21 Change (%)
Revenue	1,296.2	1,443.0	11.3%
Japan	258.8	260.0	0.5%
Ratio to Revenue	20.0%	18.0%	
United States	537.5	644.2	19.9%
Ratio to Revenue	41.5%	44.6%	
Established Markets	315.2	339.9	7.8%
Ratio to Revenue	24.3%	23.6%	
Greater China	66.3	74.4	12.2%
Ratio to Revenue	5.1%	5.2%	
International Markets	110.1	118.5	7.7%
Ratio to Revenue	8.5%	8.2%	
Others	8.4	6.0	-28.1%
Ratio to Revenue	0.6%	0.4%	

6. Investment to Property, Plant and Equipment

Depreciation/Amortisation

Unit: B¥

	FY21 APR. - JUN.	FY22 APR. - JUN.	Change	Change (%)
Investment to Property, Plant and Equipment	5.2	11.7	6.5	125.9%
Depreciation (PP&E)	9.9	9.8	-0.1	-0.8%
Amortisation of Intangible Assets (incl. software, etc.)	8.2	27.0	18.8	228.9%

- Investment to Property, Plant and Equipment does not include right-of-use asset.

	FY21 Full Year	Forecasts FY22 Full Year	Change from FY21 Change (%)
Investment to Property, Plant and Equipment	30.2	39.0	29.3%
Depreciation (PP&E)	40.1	40.0	-0.1%
Amortisation of Intangible Assets (incl. software, etc.)	39.6	42.0	6.0%

7. Sales of major products

1) Global

Unit: B¥

	FY21 APR. - JUN.	FY22 APR. - JUN.	Change	Change (%)	FY21 Full Year	Change from FY21	
						Forecasts FY22 Full Year	Change (%)
XTANDI	132.9	162.4	29.5	22.2%	534.3	642.5	20.3%
United States	68.4	83.9	15.5	22.7%	276.9	353.9	27.8%
ex-US	64.5	78.5	13.9	21.6%	257.4	288.6	12.1%
Japan	12.0	14.1	2.1	17.4%	47.2	52.6	11.4%
Established Markets	42.8	47.9	5.1	11.8%	170.1	182.1	7.1%
Greater China	1.9	3.6	1.7	90.2%	7.9	13.3	67.5%
International Markets	7.8	12.9	5.1	65.2%	32.2	40.6	26.1%
PADCEV	4.2	10.6	6.4	151.6%	21.7	36.5	68.0%
Japan	-	2.0	2.0	-	1.8	4.3	146.7%
United States	4.2	7.3	3.1	74.8%	19.5	27.6	41.4%
Established Markets	-	1.2	1.2	-	0.5	4.6	891.8%
XOSPATA	8.3	10.5	2.2	26.3%	34.1	46.2	35.5%
Japan	1.1	1.1	0.1	5.7%	3.9	4.9	26.0%
United States	4.6	5.9	1.3	29.5%	18.9	25.2	33.4%
Established Markets	2.0	2.7	0.6	31.2%	9.0	11.8	30.6%
Greater China	0.5	0.5	-0.1	-12.7%	1.5	2.4	54.0%
International Markets	0.1	0.3	0.2	170.0%	0.7	1.9	173.5%
EVRENZO	0.6	0.7	0.1	19.3%	2.6	9.9	281.2%
Japan	0.6	0.7	0.0	8.1%	2.5	6.3	152.6%
Established Markets	-	0.1	0.1	-	0.1	3.4	-
Betanis/Myrabetriq/BETMIGA	44.0	47.9	3.9	9.0%	172.3	178.7	3.7%
Japan	9.8	9.3	-0.5	-5.0%	37.5	36.2	-3.5%
United States	22.8	24.7	1.9	8.3%	87.2	90.2	3.5%
Established Markets	8.5	10.6	2.1	24.6%	36.7	40.6	10.9%
Greater China	0.7	1.0	0.3	46.8%	2.9	3.6	21.8%
International Markets	2.2	2.3	0.1	5.7%	8.1	8.1	0.0%
Prograf	45.2	51.8	6.6	14.6%	185.4	190.7	2.9%
Japan	10.2	9.6	-0.6	-6.0%	38.2	35.7	-6.6%
United States	2.1	2.5	0.4	20.3%	9.4	10.4	10.4%
Established Markets	16.2	18.4	2.2	13.4%	67.9	69.9	2.9%
Greater China	9.6	13.6	4.0	41.1%	38.1	41.3	8.3%
International Markets	7.0	7.7	0.7	9.5%	31.7	33.5	5.4%
Vesicare	7.4	4.0	-3.4	-45.4%	22.0	12.7	-42.0%

- Sales of products in Japan are shown in a gross sales basis.

- Established Markets: Europe, Canada, Australia

- Greater China: China, Hong Kong, Taiwan

- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.

- PADCEV (United States): Co-promotion revenue from Seagen

- Astellas' EVRENZO territories: Japan, Europe, the Commonwealth of Independent States, Middle East, South Africa, etc.

2) Revenue by region

(1) Japan

Unit: B¥

<Global>	Unit: B¥				FY21 Full Year	Change from FY21	
	FY21 APR. - JUN.	FY22 APR. - JUN.	Change	Change (%)		Forecasts FY22 Full Year	Change (%)
XTANDI	12.0	14.1	2.1	17.4%	47.2	52.6	11.5%
PADCEV	-	2.0	2.0	-	1.8	4.3	146.7%
XOSPATA	1.1	1.1	0.1	5.7%	3.9	4.9	26.0%
EVRENZO	0.6	0.7	0.0	8.1%	2.5	6.3	152.6%
Betanis	9.8	9.3	-0.5	-5.0%	37.5	36.2	-3.5%
Prograf (Including Gracaptor)	10.2	9.6	-0.6	-6.0%	38.2	35.7	-6.6%
Vesicare	4.6	1.2	-3.4	-73.9%	10.0	1.8	-82.4%
Hamal	0.7	0.5	-0.2	-31.7%	2.6	1.4	-45.3%
Funguard	0.4	0.3	-0.1	-29.0%	1.6	0.9	-46.6%
<Main products>							
Suglat [Family]	7.9	8.0	0.2	2.1%	30.3	33.1	9.3%
Sujanu	3.2	3.3	0.1	2.0%	12.5		
Repatha	1.5	1.6	0.2	12.2%	5.8		
Linzess	1.8	1.8	0.1	3.9%	6.9	7.8	12.8%
BLINCYTO	1.4	1.8	0.4	29.2%	6.4		
EVENITY	7.0	10.0	3.0	42.1%	31.4		
Smyraf	0.6	0.6	0.0	0.5%	2.4	3.3	39.1%
Vaccines	0.0	0.0	0.0	0.0%	5.1	8.6	67.7%
Gonax	1.3	1.3	-0.0	-1.3%	5.0	4.9	-1.3%
Cimzia	2.8	3.0	0.1	4.2%	11.2		
Myslee	1.8	1.6	-0.3	-14.5%	7.0	5.5	-22.3%
Total Rx Sales In Japanese market	67.0	66.4	-0.6	-0.9%	256.9	257.5	0.2%

- Sales of products in Japan are shown in a gross sales basis.

(2) United States

Unit: M\$

	Unit: M\$				FY21 Full Year	Forecasts	
	FY21 APR. - JUN.	FY22 APR. - JUN.	Change	Change (%)		FY22 Full Year	Change (%)
Revenue	1,221	1,240	19	1.5%	4,782	5,368	12.3%
XTANDI	625	647	22	3.5%	2,464	2,949	19.7%
PADCEV	38	57	18	47.5%	174	230	32.4%
XOSPATA	42	46	4	9.3%	168	210	24.9%
Myrbetriq	208	190	-18	-8.6%	775	752	-3.1%
Prograf	19	19	0	1.5%	84	87	3.4%
Vesicare	2	0	-3	-119.1%	15	11	-25.3%
MYCAMINE	14	6	-8	-59.6%	48	18	-62.5%
AmBisome	30	29	-1	-4.9%	135	143	6.2%
CRESEMBA	45	53	7	15.5%	194	209	7.4%
Lexiscan	196	194	-2	-1.1%	725	739	1.9%

(3) Established Markets

Unit: M€

	Unit: M€				FY21 Full Year	Forecasts	
	FY21 APR. - JUN.	FY22 APR. - JUN.	Change	Change (%)		FY22 Full Year	Change (%)
Revenue	591	642	51	8.7%	2,414	2,517	4.3%
XTANDI	325	347	22	6.8%	1,303	1,349	3.5%
PADCEV	-	9	9	-	4	34	859.1%
XOSPATA	15	19	4	25.3%	69	88	26.3%
EVRENZO	-	0	0	-	1	25	-
BETMIGA	65	77	12	19.1%	281	301	7.2%
Prograf	123	133	10	8.4%	520	518	-0.4%
Vesicare	11	11	0	2.1%	42	35	-16.1%
Omnice	17	17	0	0.4%	67	64	-5.2%
MYCAMINE	7	5	-2	-24.3%	22	15	-29.0%

- Established Markets: Europe, Canada, Australia

(4) Greater China

Unit: B¥

	FY21 APR. - JUN.	FY22 APR. - JUN.	Change	Change (%)
Revenue	16.4	23.2	6.7	41.0%
XTANDI	1.9	3.6	1.7	90.2%
XOSPATA	0.5	0.5	-0.1	-12.7%
BETMIGA	0.7	1.0	0.3	46.8%
Prograf	9.6	13.6	4.0	41.1%
Vesicare	0.3	0.3	0.0	4.2%
Harnal	2.0	2.4	0.4	20.3%
MYCAMINE	0.6	0.8	0.2	35.8%
Feburic	0.6	0.8	0.2	35.0%

- Greater China: China, Hong Kong, Taiwan

	FY21 Full Year	Forecasts FY22 Full Year	Change from FY21 Change (%)
	66.3	74.4	12.2%
	7.9	13.3	67.5%
	1.5	2.4	54.0%
	2.9	3.6	21.8%
	38.1	41.3	8.3%
	1.0	1.0	-5.8%
	8.2	8.0	-2.3%
	2.9	1.4	-53.4%
	2.9	2.8	-2.5%

(5) International Markets

Unit: B¥

	FY21 APR. - JUN.	FY22 APR. - JUN.	Change	Change (%)
Revenue	27.8	31.8	4.0	14.5%
XTANDI	7.8	12.9	5.1	65.2%
XOSPATA	0.1	0.3	0.2	170.0%
BETMIGA	2.2	2.3	0.1	5.7%
Prograf	7.0	7.7	0.7	9.5%
Vesicare	0.9	1.1	0.2	22.9%
Harnal	4.3	4.2	-0.1	-3.3%
MYCAMINE	1.6	1.4	-0.2	-13.0%

- International Markets: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.

	FY21 Full Year	Forecasts FY22 Full Year	Change from FY21 Change (%)
	110.1	118.5	7.7%
	32.2	40.6	26.1%
	0.7	1.9	173.5%
	8.1	8.1	0.0%
	31.7	33.5	5.4%
	3.7	3.9	5.1%
	16.1	17.8	10.3%
	6.1	6.2	1.1%

8. Consolidated statements of financial position

Unit: B¥

	FY21 End	FY22 Q1 End	Change
Assets	2,332.4	2,481.8	149.4
Non-current assets	1,409.0	1,492.6	83.5
Property, plant and equipment	269.0	280.2	11.1
Goodwill	303.0	334.3	31.2
Intangible assets	623.4	639.8	16.4
Trade and other receivables	29.8	27.4	-2.4
Investments accounted for using equity method	10.0	11.7	1.7
Deferred tax assets	72.3	92.1	19.8
Other financial assets	91.8	94.3	2.4
Other non-current assets	9.5	12.8	3.3
Current assets	923.4	989.3	65.9
Inventories	153.1	164.8	11.8
Trade and other receivables	382.5	438.4	56.0
Income tax receivable	21.5	18.1	-3.4
Other financial assets	21.3	23.7	2.4
Other current assets	29.0	31.1	2.1
Cash and cash equivalents	316.0	313.0	-3.0

Unit: B¥

	FY21 End	FY22 Q1 End	Change
Equity and Liabilities	2,332.4	2,481.8	149.4
Equity	1,460.3	1,539.1	78.7
Equity attributable to owners of the parent	1,460.3	1,539.1	78.7
Share capital	103.0	103.0	-
Capital surplus	179.5	179.0	-0.4
Treasury shares	-13.9	-23.4	-9.4
Retained earnings	944.3	925.0	-19.3
Other components of equity	247.5	355.4	107.9
Liabilities	872.1	942.8	70.7
Non-current liabilities	184.7	202.3	17.6
Trade and other payables	0.7	4.9	4.2
Deferred tax liabilities	5.8	6.2	0.4
Retirement benefit liabilities	37.2	36.3	-0.9
Provisions	5.8	7.7	1.9
Other financial liabilities	95.9	111.6	15.7
Other non-current liabilities	39.2	35.5	-3.7
Current liabilities	687.4	740.5	53.1
Trade and other payables	130.7	152.2	21.5
Income tax payable	32.4	18.9	-13.5
Provisions	16.6	17.6	1.0
Other financial liabilities	185.0	206.5	21.5
Other current liabilities	322.8	345.4	22.7

R&D Pipeline

The list shows the development status in the target diseases for which we aim to obtain approval in Japan, the United States, Europe and/or China.

As of Jul 2022

Underlined items indicate changes from the previous announcement in Apr 2022.

XTANDI and Strategic products (1/2)

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
enzalutamide MDV3100 (XTANDI)	Small molecule	Androgen receptor inhibitor	Metastatic castration-sensitive prostate cancer	China P-III	Pfizer	
			Non-metastatic castration-sensitive prostate cancer	P-III		
enfortumab vedotin ASG-22ME (PADCEV)	Antibody-drug conjugate (ADC)	Nectin-4 targeted ADC	Metastatic urothelial cancer, previously untreated (first line; combo with pembrolizumab)	P-III	In-house [Co-development with Seagen]	
			Muscle-invasive bladder cancer (combo with pembrolizumab)	P-III		
			Other solid tumors	P-II		
			Non-muscle-invasive bladder cancer	P-I		
gilteritinib ASP2215 (XOSPATA)	Small molecule	FLT3 inhibitor	Post-chemotherapy maintenance acute myeloid leukemia	P-III	In-house	
			Post-hematopoietic stem cell transplant maintenance acute myeloid leukemia	P-III		
			Newly diagnosed acute myeloid leukemia with high intensity induction of chemotherapy	P-III		
			Newly diagnosed acute myeloid leukemia with low intensity induction of chemotherapy	P-I		
			Acute myeloid leukemia in pediatric patients	P-III		

XTANDI and Strategic products (2/2)

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
zolibetuximab IMAB362	Antibody	Anti-Claudin 18.2 monoclonal antibody	Gastric and gastroesophageal junction adenocarcinoma	P-III	In-house (Ganymed)	
			Pancreatic adenocarcinoma	P-II		
roxadustat ASP1517/FG-4592 (EVRENZO)	Small molecule	HIF-PH inhibitor	Chemotherapy-induced anemia	P-II	FibroGen	Astellas has rights in Japan, Europe, the Commonwealth of Independent States, the Middle East, and South Africa
fezolinetant ESN364	Small molecule	NK3 receptor antagonist	Vasomotor symptoms associated with menopause	US <u>Submitted (Jun 2022)</u>	In-house (Ogeda)	
				Europe P-III China		
				Japan P-II		
resamirigene bilparovect AT132	Gene therapy (AAV-based gene therapy)	MTM1 gene replacement to express myotubularin	X-linked myotubular myopathy	P-II	In-house (Audentes Therapeutics)	

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

** Compounds with "In-house" in this column include ones discovered by collaborative research.

Updates from the previous announcement (Apr 2022):

enfortumab vedotin (ASG-22ME): Removed the description of the approval in Europe in Apr 2022 for locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a PD-1/L1 inhibitor.

fezolinetant: NDA submitted in US in Jun 2022 for moderate to severe vasomotor symptoms associated with menopause.

Projects with Focus Area approach (1/2)

Primary Focus	Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensors **	Remarks
Immunology	ASP9801	Oncolytic virus	Oncolytic virus carrying IL-7 and IL-12	Cancer	P-I	Tottori University [Discovered through collaborative research]	
	ASP7517	Cell therapy (artificial adjuvant vector cells)	WT1 loaded artificial adjuvant vector cell	Acute myeloid leukemia and myelodysplastic syndrome	P-II	RIKEN [Discovered through collaborative research]	
				Solid tumor	P-I		
	ASP0739	Cell therapy (artificial adjuvant vector cells)	NY-ESO-1 loaded artificial adjuvant vector cell	Cancer	P-I	RIKEN [Discovered through collaborative research]	
	ASP1570	Small molecule	DGKζ inhibitor	Cancer	P-I	In-house	
ASP2138	Antibody	Anti-Claudin 18.2 and anti-CD3 bispecific antibody	Gastric and gastroesophageal junction adenocarcinoma, pancreatic adenocarcinoma	P-I	Xencor [Discovered through collaborative research]		
Blindness and Regeneration	ASP7317	Cell therapy	Retinal pigment epithelium cells	Geographic atrophy secondary to age-related macular degeneration, Stargardt disease	P-I	In-house (Ocata Therapeutics)	
Mitochondria Biology	bocidelpar ASP0367/MA-0211	Small molecule	PPARδ modulator	Primary mitochondrial myopathies	P-II	In-house (Mitobridge)	
				Duchenne muscular dystrophy	P-I		
	ASP8731/ML-0207	Small molecule	BACH1 inhibitor	Sickle cell disease	P-I	In-house (Mitobridge)	

Projects with Focus Area approach (2/2)

Primary Focus	Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
Genetic regulation	resamirigene bilparvovec AT132 ***	Gene therapy (AAV-based gene therapy)	MTM1 gene replacement to express myotubularin	X-linked myotubular myopathy	P-II	In-house (Audentes Therapeutics)	
	AT845	Gene therapy (AAV-based gene therapy)	GAA gene replacement to express GAA enzyme	Pompe disease	P-I	In-house (Audentes Therapeutics)	
(Other projects with Focus Area approach)	FX-322	Small molecule	Inner ear progenitor cell activator (combination of GSK-3 inhibitor and HDAC inhibitor)	Sensorineural hearing loss	P-II	Frequency Therapeutics	Astellas has rights in Ex-US markets
	ASP0598	Recombinant protein	Recombinant human heparin-binding epidermal growth factor-like growth factor	Chronic tympanic membrane perforation	P-I	Auration Biotech	
	ASP3082	Small molecule	KRAS G12D degrader	Cancer	P-I	In-house	

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

** Compounds with "In-house" in this column include ones discovered by collaborative research.

*** AT132 is also listed in "XTANDI and Strategic products".

Updates from the previous announcement (Apr 2022):

ASP3082: Described the classification.

Others

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
mirabegron YM178	Small molecule	β_3 receptor agonist	Neurogenic detrusor overactivity in pediatric patients	Europe P-III	In-house	
			Overactive bladder in pediatric patients	Europe P-III		
peficitinib ASP015K	Small molecule	JAK inhibitor	Rheumatoid arthritis	China P-III	In-house	
isavuconazole	Small molecule	Azole antifungal	Invasive aspergillosis and mucormycosis in pediatric patients	US P-II	Basilea	
ASP8062	Small molecule	GABA _B receptor positive allosteric modulator	Alcohol use disorder	P-I	In-house	

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

** Compounds with "In-house" in this column include ones discovered by collaborative research.

Updates from the previous announcement (Apr 2022):

ASP8062: Discontinued the development for opioid use disorder in Phase 2 due to strategic prioritization.

Rx+ Program

As of July 2022

Sphere (Business area)	Program	Concept	Status *	Partner	Remarks
Chronic disease progression prevention	Game application for exercise support	Smartphone application to support exercise using motion sensing technology for people who needs regular exercise	Under development	BANDAI NAMCO Entertainment	
	Fit-eNce	Service to provide scientifically evidenced exercise programs and systems supporting regular exercise	Under test marketing		
	Fit-eNce Home	Service to provide scientifically evidenced exercise programs and systems supporting regular exercise at home	Under test marketing		
	BlueStar	Digital therapeutics for adults with diabetes	Under clinical trial preparation	Welldoc	
Patient outcome maximization	pudexacianinium chloride ASP5354	Precision surgery-guide enabling identification of ureter in hysterectomy and colorectal surgery etc.	P-III		

* The list shows the most advanced stage if the stages are different depending on the region.